Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial Copyright: alphaspirit / 123RF Stock Photo On September 15, 2025, Spyre Therapeutics Inc. (NASDAQ:SYRE) announced the enrollment of the first patient in its Phase 2 SKYWAY trial targeting multiple autoimmune diseases. This randomized study will assess the company's lead antibody program in patients who showed no response to standard treatments. As this is its second Phase 2 program, Spyre Therapeutics Inc. (NASDAQ:SYRE) expects initial data in 2026, with several proof-of-concept readouts planned over the next two years. Spyre Therapeutics Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company, develops therapies for inflammatory bowel disease. It is one of the Best Debt Free Stocks. While we acknowledge the potential of SYRE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock th
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
- Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.MarketBeat
- Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SYRE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 12/3/25 - Form 4
- 11/5/25 - Form 4
- 11/4/25 - Form 8-K
- SYRE's page on the SEC website